6 funding opportunities found in this category. Change the order of results: Newest First Oldest First Expiring Soonest Expiring Latest Lowest Award to Highest Highest Award to Lowest
Arthritis Foundation 2012 Research Grants Request for Applications
Application Deadline: February 6, 2012 (5:00 pm Eastern)
The Arthritis Foundation is pleased to announce the 2012 RFA for Clinical to Research Transition Awards, Postdoctoral Fellowships, Doctoral Dissertation Awards, and New Investigator Grants.
Proposals must be submitted through proposalCENTRAL.
Application forms available through proposalCENTRAL. Do not submit more than one application per applicant.
TRAINING AWARDS
Training Awards are intended to provide support for young investigators at the beginning of their research careers as they investigate questions related to arthritis and musculoskeletal diseases. The institution or supervisor is expected to provide any additional needed support. Clinical to Research Transition Award (CRTA)
This award is for MDs/DOs who are clinically trained in adult or pediatric rheumatology and intend to pursue a research career in academic rheumatology. The award is designed to allow candidates to gain initial research experience in preparation for application for mentored awards requiring research experience and productivity such as the ACR/REF Rheumatology Scientist Development Award, the ACR/REF Rheumatology Investigator Award, NIH Mentored Career Development Award (K23, K08) or other similar awards. CRTA funds may be used to supplement salary derived from an NIH T32 Training Grant.
Eligibility Criteria
Applicants may not simultaneously accept the CRTA and another mentored training award. However, if the applicant subsequently applies for and receives a mentored training award (see above), the CRTA may be re-budgeted and funded for a second year. The CRTA will not be allowed to continue if the awardee received individual research funding. Applicants must be within the final year of training leading to board eligibility for either pediatric or adult rheumatology or be within a two-year time limit after completion of clinical training and have less than two years of research experience when funding beings on July 1, 2012. Candidates holding PhD or MD/PhD degrees are not eligible, but those holding Masters degrees who meet the other requirements are eligible.
Citizenship/Work Abroad
U.S. citizenship is not required but the applicant must hold a full-time appointment at a U.S. institution. Research may be conducted at institutions outside of the U.S.
Postdoctoral Fellowship
Provides support for individuals with PhD, MD or DVM degrees who are not eligible for CRTA awards. Funding is for a maximum period of two-years. A minimum of seventy-five percent time must be devoted to arthritis-focused research. The award amount is $50,000 per year for salary and fringe benefits or research-related costs. Indirect costs are not allowed.
Academic Background - As of the beginning date of the award, individuals must have received a doctoral degree from an accredited institution. Research Background - Applicants are not eligible after four years of post degree laboratory experience. This experience is counted from the completion of the terminal degree until the beginning date of the award (as early as July 1). Applicants will not count time spent in clinical training defined as more than 50% time in clinical activities. Individuals at or above the Assistant Professor level or those who have tenured positions are ineligible to apply for the award.
Fellowships may be awarded to U.S. citizens for study abroad if it seems in the best interest of the candidate's future career. However, no provisions are made for travel expenses. Foreign citizens may be funded only if their training is conducted at a U.S. institution. Awards may not be transferred outside the U.S.
Doctoral Dissertation Award for Arthritis Health Professionals
Provides one or two years of salary and/or research support. The research project must be related to arthritis management and/or comprehensive patient care in rheumatology practice, research or education. Not for laboratory research. The award amount is $30,000 per year.
The Doctoral Dissertation Awards are designed for pre-doctoral students who will receive doctoral degrees from U.S. institutions. Applicants should be entering the research phase of their degree program. The thesis supervisor must approve the project which must be related to arthritis management, comprehensive patient care in rheumatology practice, or arthritis research. Suitable studies include, but are not limited to, functional, behavioral, nutritional, educational, occupational, or epidemiological aspects of patient care and management. Drug studies and laboratory in vitro studies are not appropriate. A candidate must have membership or eligibility for membership in his/her professional organization.
US citizenship is required. Awards may be used to study abroad if it seems in the best interest of the candidate's future career and has approval from the degree granting U.S. institution. However, no provisions are made for travel expenses.
New Investigator Grant for Arthritis Health Professionals
New Investigator Awards are intended to provide the support for young Arthritis Health Professionals such as physical therapists as they initiate independent research related to arthritis. These grants typically cover the cost of salaries, consumable supplies, equipment, travel and other items to conduct the proposed research. Applicants must be establishing their first independent, self-directed laboratory for whom the institution provides space and other resources. The New Investigator Award provides funding for a period of up to two years and is not for wet bench laboratory research. Suitable studies include, but are not limited to, functional, behavioral, nutritional, occupational, or epidemiological aspects of patient care and management. The award amount is $50,000 per year.
New Investigator Grants are designed for individuals with a doctoral degree and demonstrated research experience related to arthritis and/or the care of patients with arthritis or education relevant to arthritis. These awards are limited to applicants who have received a doctoral degree within the last five years prior to the submission date. MDs and individuals at the NIH and CDC are not eligible. A candidate must have membership or eligibility for membership in his/her professional organization.
Applicants must be a U.S. citizen or permanent resident at the time of application. Awards may not be transferred outside of the U.S.
PEER REVIEW
All research proposals funded through the Arthritis Foundation undergo a national peer review process in which proposals are ranked according to scientific merit. An online review mechanism is used to assign an initial priority score. Each grant will be evaluated and scored by at least three experts in the field.
ASSISTANCE WITH APPLICATIONS
For questions regarding eligibility, policies, terms and conditions or application instructions, please contact the Arthritis Foundation Research Department at Grantsupport@arthritis.org or 404.965.7537. For technical assistance with proposalCENTRAL, please call 1.800.875.2562.
Call for Applications: American College of Rheumatology Research and Education Foundation for Investigator-Initiated Clinical Trials that Address Clinical Aspects of Rheumatoid Arthritis
The American College of Rheumatology Research and Education Foundation is soliciting applications for investigator-initiated clinical trials that address clinical aspects of rheumatoid arthritis. Outcomes from these grants should lead to new insights into the treatment of RA. All applications must be relevant to the purpose and goals of the Within Our Reach campaign. It is expected that these clinical trials will include prospective studies designed to answer questions about biomedical or behavioral interventions, e.g., investigational drugs or investigational medical devices, or new ways of using known treatments relevant to RA. It is hoped that these trials will determine whether new biomedical or behavioral interventions are safe, efficacious, and effective.
For purposes of this program, the term ‘clinical trial’ refers to a broadly based prospective clinical investigation involving a large number of human subjects for the purpose of evaluating an experimental intervention in comparison with a standard or control intervention or comparing two or more existing treatments. The aim of such investigation is to provide evidence leading to a scientific basis for consideration of a change in health policy or standard of care. The definition includes pharmacologic, non-pharmacologic, and behavioral interventions for disease prevention, prophylaxis, diagnosis, or therapy. Community- and other population-based intervention trials also are included.
The proposed trials must be hypothesis-driven, milestone-defined, related to the research mission of the Within Our Reach campaign and considered high priority by the Foundation. Investigators are encouraged to visit the REF website for additional information about the campaign.
The total number of trials funded will depend upon the number and quality of the applications received; however it is anticipated that a maximum of two trials will be funded. The trials will be funded for three years at up to $1,000,000 per year, including eight percent indirect costs.
Previous recipients of Within Our Reach grants may apply. Individuals at the NIH and CDC are not eligible to apply as Principal Investigators for either type of grant, but may serve as part of the research team. These individuals may not receive funds from this program, and must obtain appropriate internal clearances and include documentation of such in the application.
Please visit the website at http://www.rheumatology.org/ref/awards/WOR.asp for more information and to download the full Request for Proposals. All applicants must submit a letter of intent via the online submission form no later than March 1, 2012. Applications must be postmarked by May 1, 2012.
Alliance for Lupus Research 2012 Grant Application Announcment
The Alliance for Lupus Research (ALR) is pleased to announce that the applications for the ALR’s Functional Genomics and Molecular Genetic Pathways in SLE grants are now available online.
Research Grants: Approved grant applications will be eligible to receive a 2-year award for up to $350,000 USD (up to $175,000 USD per year for two years). Research grants must provide evidence of preliminary data.
Pilot Grants: Approved grant applications will be eligible to receive a 1-year award for up to $75,000 USD. Pilot grants are for projects that are not supported by preliminary data. Guidelines for application and submission are also available on the websites listed above.
Deadlines associated with this grant program are as follows:
Grant Applications: Due to ALR by February 15, 2012
Applications submitted should focus on two principal areas: (1) functional validation to determine which candidate genes/variants identified in human lupus have an authentic role in the disease and (2) detailed elucidation of the molecular pathways modulated by these candidate genes/variants identified in human lupus.
There are public resources available to facilitate functional validation of genes/variants involved in lupus. ALR encourages investigators to take advantage of all of these resources. All proposals submitted must be based on information in the public domain.
Responsive applications will propose research to elucidate the functional implications of the genetic variants identified in human lupus studies. Lupus-associated genes studied in animal models that are not among those also identified in human studies are not appropriate topics for this grant mechanism.
ALR will focus support on:
Human Studies: Functional validation studies could use human DNA samples from phenotypically well-characterized individuals to correlate a gene variant with a particular phenotype. Such human studies are particularly encouraged.
Genetic Models: Established genetic models as well as emerging genetic models can be used to look at in vivo gene/variant function.
RNA interference: RNAi depletion of candidate genes in cells, tissues or whole organisms can be used to identify phenotypes.
Imaging strategies: Imaging of cell trafficking in vivo might be useful in characterizing the impact of lupus-associated gene variants on immune responses or inflammation.
Systems-level approaches: Bioinformatic resources (i.e., interactome, gene expression, proteomic, metabolomic, and anatomical databases) can be mined to generate testable hypotheses concerning the function of candidate genes and groups of genes.
Cellular or circuit-level approaches: Studies might compare gene/variant functional consequences at the cellular and circuit levels, especially with respect to a drug challenge.
Epigenetics: Functional validations of epigenetic mechanisms of gene regulation in the context of lupus, including potential maternal and paternal imprinting or X chromosome inactivation, are of interest.
Comparison of wild type and gene variant functions: The molecular alteration associated with a gene variant frequently does not reveal whether the function of a particular gene is increased, decreased, or leads to unexpected functional consequences. Approaches using in vivo transgenes, in vitro biochemical assays, or other validation methods that can address these issues will help to identify the most promising molecular targets for therapeutic interventions.
Identification of functionally significant sequences in disease-associated genomic regions: While some genomic regions show strong statistical association with a diagnosis of SLE, in many cases the specific sequences responsible for the association have not yet been identified. Deep sequencing approaches can be used to define the specific regulatory or coding sequences responsible for the association with SLE and their impact on cell function.
Application Requirements
Applications are open to investigators working at established research institutions (both for profit and not-for profit) as well as investigators at state health agencies, the FDA, VA and at intramural divisions of NIH. Applications may be submitted by investigators working anywhere in the world. Non-U.S. applicants whose projects involve human subjects must work at institutions that have human subjects committees that operate in a substantially similar manner to a U.S. Institutional Review Board.
If you have any questions or require any additional information regarding the application process, please contact Diomaris Gonzalez, Assistant Director of Research Administration at (212) 218-2840; 1-800-867-1743 or at research.admin@lupusresearch.org.
Call for Applications: Scleroderma Foundation Established Investigator Grant
Grant Application Deadline: Sept. 15th annually by 5 p.m. EST
If the 15th falls on a Sat. or Sun., then the following Monday at 5 p.m. EST will be the deadline.
Purpose: The Scleroderma Foundation is seeking applications from promising established investigators both inside and outside the field of SSc research who wish to propose pilot studies to obtain preliminary data dealing with a highly innovative and/or highly relevant theme related to SSc. This grant will support pilot research that is likely to lead to more substantial unlimited research project grants from federal or non-federal sources.
Eligibility Requirements: Applications may be submitted by domestic non-profit organizations, public and private such as universities, colleges, hospitals and laboratories. Foreign organizations and institutions are eligible. Applicants must have a doctorate degree in Medicine, Osteopathy, Veterinary Medicine or one of the sciences, must have completed a postdoctoral fellowship, have been Principal Investigator on grants from the Scleroderma Foundation or other national, private or government agencies in the past.
Investigators who have questions about eligibility should contact the Scleroderma Foundation (see below).
Mechanism of Support: Applicants may request up to $75,000 (Up to 8% of the Direct Costs per year of award may be set aside as indirect costs. The indirect cost amount will be subtracted from the yearly total [up to $75,000) of the award) per year for up to two years (total for 2 years not to exceed $150,000). These awards are not renewable. Before completion of this grant, investigators are encouraged to seek more substantial continuing support for research through other grant mechanisms through private or government agencies. Replacement of the Principal Investigator on this award is not permitted. There will be no routine escalation for future years.
Awards are contingent on the availability of funds and the receipt of sufficiently meritorious applications meeting the stated eligibility requirements.
Research Objectives: The Scleroderma Foundation Innovative Grant is designed to facilitate highly innovative or highly relevant and meritorious pilot projects by established investigators in areas of research related to SSc that will culminate in more substantial funding from Federal or non-federal granting agencies such as the National Institutes of Health, National Science Foundation and the Department of Defense or Veterans Affairs.
Appropriate research areas may include but are not limited to the following as they relate to scleroderma:
Vascular manifestations. Studies of animal models. Therapeutic modalities. Mechanisms of end organ damage. Immunologic studies. Endothelial cell biology. Fibroblast biology. Models and markers of gender and genetic factors. Cell signaling. Epidemiology studies. Matrix biology. Stem cell biology. Health services research (e.g. quality of life, health care delivery.) Study of clinical manifestation.
Scleroderma Foundation 300 Rosewood Drive, Suite 105 Danvers, MA 01923
Phone: (978) 463-5843 (8:30 a.m. to 5 p.m. ET, Monday through Friday) Fax: (978) 463-5809 Toll-free: (800) 722-HOPE (4673)
Call for Applications: Scleroderma Foundation New Investigator Grant
Purpose: The Scleroderma Foundation is seeking applications from promising new investigators who hold faculty or equivalent positions and who wish to pursue a career in research related to systemic sclerosis (SSc, scleroderma). This grant will support promising research that is likely to lead to individual research project grants.
Eligibility Requirements: Applications may be submitted by domestic non-profit organizations, public and private such as universities, colleges, hospitals and laboratories. Foreign organizations and institutions are not eligible. These new investigator grants may not be used to support thesis or dissertation research or fellowship training. Applicants must have a doctoral degree in Medicine, Osteopathy, Veterinary Medicine or one of the sciences and must have completed a postdoctoral fellowship by the grant award date. Applicants who have been a Principal Investigator on grants from the Scleroderma Foundation or other national, private or government agencies other than fellowship grants are not eligible for this award.
Mechanism of Support: Applicants may request up to $50,000 (Up to 8% of the Direct Costs per year of award may be set aside as indirect costs. The indirect costs will be subtracted from the yearly total (up to $50,000) of the award.) per year for up to three years (total for three years not to exceed $150,000). These awards are not renewable. Before completion of this grant, investigators are encouraged to seek continuing support for research through other grant mechanisms through private or government agencies. Replacement of the Principal Investigator on this award is not permitted. There will be no routine escalation for future years.
Research Objectives: The Scleroderma Foundation New Investigator Grant is designed to facilitate the entry of promising new investigators into areas of research related to SSc.
American College of Rheumatology Research and Education Foundation/Arthritis Foundation Career Development Bridge Funding Award
Cycle III Applications due: 5/1/2012
The REF and the Arthritis Foundation have partnered to create the ACR REF/AF Career Development Bridge Funding Award to help foster investigators in the early stages of their career as they prepare their NIH K08/K23 application resubmissions. Our intent is to provide up to one-year of bridge funding to support these promising applicants as they resubmit their applications. We believe this support will provide the encouragement—and the protected time—they need to succeed in obtaining their K awards, and ultimately, to become independent researchers.
Amount of Award The REF will provide total support up to $75,000 in direct costs. The amount of the award can be divided between salary and fringe benefits and/or research costs up to a maximum of $25,000. Fringe benefits may not exceed 30%. The total salary requested must be based on a full-time, 12 month faculty appointment requiring the candidate to devote a minimum of 75% of full-time professional effort to conducting research with the remaining effort being devoted to activities related to the development of a successful research career. The REF does not allow indirect costs to the institution.
For more information about this award, please contact the REF office by e-mail or by phone at (404) 633-3777.
1
